When compared to the broader market, Verastem Oncology has shown exceptional performance. The company’s stock has surged 30.57% year-to-date, a stark contrast to the S&P 500’s meager performance of -0 ...

Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ovarian carcinoma. Click to read.

an oral RAF/MEK clamp, in combination with defactinib. Under development at US pharma company Verastem Oncology (Nasdaq: VSTM ...